Ten Commandments for 2021 Guidelines on Valvular Heart Disease

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

Since the latest version to the Valvular Heart Disease Guidelines from the European Society of Cardiology, plenty of evidence has been accumulating, finally leading to this updated version. 

In this regard, below you will find what has been called “10 commandments” that sum up this new document, to keep you in the loop. 

  • The incidence of degenerative valvulopathy continues to increase in industrialized countries, with the elderly as the most affected seeing as they present multiple comorbidities. On the other hand, rheumatic heart disease continues to be fairly frequent in developing countries. 
  • We give emphasis to patient centered assessments. When considering an intervention, we should assess patient expectations and values. This can only be carried out by a multidisciplinary team working in a specialized heart valve center. 
  • Echocardiograms are key to the diagnosis of valvulopathy, to measure severity and establish prognosis. Other studies such as CT scans, MRIs and biomarkers are starting to play a more central role. 
  • Based on randomized trial outcomes on its intervention, we have new definitions of severity in secondary mitral valve regurgitation.  
  • To prevent stroke in patients with atrial fibrillation, we recommend direct anticoagulants in patients with aortic stenosis, mitral or aortic regurgitation and patients with bioprosthesis 3 months post implantation. We recommend single antiaggregation for patients undergoing TAVR with no other anticoagulation indication. 
  • In places with high surgical experience and post operative support, you can consider early intervention in asymptomatic patients at low risk of aortic stenosis, aortic or mitral regurgitation, or tricuspid regurgitation. 

Read also: New Valvular Heart Disease Guidelines with Key TAVI and Mitral Regurgitation Updates.


  • New information on randomized controlled trials comparing TAVR against CABG have contributed to clarify the role each procedure has in the treatment of low-risk patients. Choosing the most adequate strategy (TAVR vs CABG) should be in the hands of a multidisciplinary team who will consider patient age, surgical risk, clinical and anatomical characteristics (particularly femoral approach feasibility) center experience and results and, last but not least, patient preference. 
  • Edge to Edge repair has been compared to optimal medical treatment in secondary mitral regurgitation, resulting in an upgraded recommendation of this strategy for patients meeting the criteria that predict clinical improvement. 
  • A lot of information has been published on valve in valve; this has led to upgrading its recommendation. 
  • Lastly, encouraged by the published information, there is a potential role for transcatheter tricuspid repair in inoperable asymptomatic patients with tricuspid failure

Original Title: The “ten commandments” for the 2021 ESC/EACTS Guidelines on valvular heart disease.

Reference: Alec Vahanian et al. Eur Heart J. 2021 Nov 1;42(41):4207-4208. doi: 10.1093/eurheartj/ehab626.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

UNICORN Technique to Prevent Coronary Obstruction During TAVI: Initial Results From a Multicenter Study

Coronary obstruction is an uncommon but potentially catastrophic complication of transcatheter aortic valve implantation (TAVI), particularly in valve-in-valve procedures, TAV-in-TAV interventions, or in patients...

Hemodynamic Outcomes of Edge-to-Edge Repair in Degenerative and Functional Mitral Regurgitation

Transcatheter edge-to-edge mitral valve repair (M-TEER) has become an established therapeutic option for mitral valve disease. Among the available techniques, M-TEER using the MitraClip...

SAPIEN 3 TAVI Durability: Ten-Year Follow-Up in Intermediate-Risk Patients

The durability of transcatheter bioprosthetic valves used in TAVI remains one of the key unanswered questions as indications continue to expand toward patients with...

Inflammation after TAVI: An Emerging Therapeutic Target?

Conduction disturbances and the need for permanent pacemaker implantation remain common complications following TAVI, with an incidence approaching 15%. Although they have traditionally been...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

UNICORN Technique to Prevent Coronary Obstruction During TAVI: Initial Results From a Multicenter Study

Coronary obstruction is an uncommon but potentially catastrophic complication of transcatheter aortic valve implantation (TAVI), particularly in valve-in-valve procedures, TAV-in-TAV interventions, or in patients...

Supera vs. Eluvia at 3 Years in Severely Calcified Femoropopliteal Lesions

Severe calcification remains one of the main predictors of restenosis and the need for repeat revascularization following endovascular treatment of femoropopliteal disease. In this...

Is IVUS Always Necessary for Left Main Coronary Artery PCI?

Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery is a highly complex procedure because of the large amount of myocardium at...